Dr. Andrew Zhu Joins Chemokine Therapeutics' Clinical Advisory Board

15-Aug-2008

Chemokine Therapeutics Corp. announced that Dr. Andrew Zhu has joined the Company's oncology Clinical Advisory Board. The Advisory Board plays an important role in guiding the CTCE-9908 clinical development program.

Dr. Andrew Zhu is an attending oncologist as well as the director of Liver Cancer Research at Massachusetts General Hospital Cancer Center. He is also a staff physician at Dana-Farber Cancer Institute, and a member of Dana-Farber Harvard Cancer Center in Boston, Massachusetts. Dr. Zhu is an assistant professor of medicine at Harvard Medical School and is board-certified in internal medicine and medical oncology, and holds clinical research interests in developing novel treatments for gastrointestinal cancers including hepatocellular carcinoma, bile duct tumor and colorectal cancer.

Dr. Zhu earned his medical degree from Beijing Medical University in Beijing, China. He went on to study microbiology and obtain his Ph.D. at Columbia University in New York City, New York. Dr. Zhu finished his residency at Yale-New Haven Hospital, Yale School of Medicine in New Haven Connecticut and his fellowship in medical oncology and hematology at the Memorial Sloan-Kettering Cancer Center in New York City, Center, New York.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

Last viewed contents

Currently positioned only 5th, China is the fastest growing biotech market in the world

BGU researchers make scientific breakthrough in the fight against neurodegenerative diseases - BGN Technologies secures funding of over $1m. to develop patented treatment

Pivotal phase IIIa trials for Organon's novel oral contraceptive, NOMAC/E2, complete recruitment

Gene Logic Expands GeneExpress Product Line, Launches GeneExpress Women's Health DataSuite - New Product Enables Analysis of Distinctions in Female and Male/ Female Gene Expression

Cangene's VIG (Vaccinia Immune Globulin Intravenous) contract with U.S. government extended for another five years

MediGene successfully completes patient recruitment into EndoTAG(TM)-1 Phase II breast cancer trial

Immatics Enters Collaboration with Cancer Research UK to Develop Multi-target Rationally Designed Therapeutic Cancer Vaccine - IMA950 to enter Phase I development for glioblastoma, the most aggressive form of brain cancer

New findings about stem cells in the brain of patients with epilepsy

EMA starts rolling review of COVID-19 vaccine Vidprevtyn - Protein-based vaccine developed by Sanofi Pasteur

EMA starts rolling review of COVID-19 vaccine Vidprevtyn - Protein-based vaccine developed by Sanofi Pasteur

Researchers use sugar to halt esophageal cancer in its tracks

Anika Therapeutics Announces Termination of Worldwide Development and Commercialization Partnership with OrthoNeutrogena - Company Files Pre-Market Approval Applicaton for Cosmetic Tissue Augmentation Product

Scottish Life Sciences Sector set to Benefit from South Korean Institute Opening in Glasgow